Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges
- PMID: 32081636
- PMCID: PMC7127800
- DOI: 10.1016/j.ijantimicag.2020.105924
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges
Abstract
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2; previously provisionally named 2019 novel coronavirus or 2019-nCoV) disease (COVID-19) in China at the end of 2019 has caused a large global outbreak and is a major public health issue. As of 11 February 2020, data from the World Health Organization (WHO) have shown that more than 43 000 confirmed cases have been identified in 28 countries/regions, with >99% of cases being detected in China. On 30 January 2020, the WHO declared COVID-19 as the sixth public health emergency of international concern. SARS-CoV-2 is closely related to two bat-derived severe acute respiratory syndrome-like coronaviruses, bat-SL-CoVZC45 and bat-SL-CoVZXC21. It is spread by human-to-human transmission via droplets or direct contact, and infection has been estimated to have mean incubation period of 6.4 days and a basic reproduction number of 2.24-3.58. Among patients with pneumonia caused by SARS-CoV-2 (novel coronavirus pneumonia or Wuhan pneumonia), fever was the most common symptom, followed by cough. Bilateral lung involvement with ground-glass opacity was the most common finding from computed tomography images of the chest. The one case of SARS-CoV-2 pneumonia in the USA is responding well to remdesivir, which is now undergoing a clinical trial in China. Currently, controlling infection to prevent the spread of SARS-CoV-2 is the primary intervention being used. However, public health authorities should keep monitoring the situation closely, as the more we can learn about this novel virus and its associated outbreak, the better we can respond.
Keywords: 2019-nCoV; COVID-19; China; Epidemic; Remdesivir; SARS-CoV-2.
Copyright © 2020 Elsevier Ltd. All rights reserved.
Figures
![Fig 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/7127800/bin/gr1_lrg.gif)
![Fig 2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/7127800/bin/gr2_lrg.gif)
![Fig 3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/7127800/bin/gr3_lrg.gif)
Comment in
-
Between Scylla and Charybdis: Navigating Chronic Pain Patients Through the COVID-19 and the Opioid Pandemic.Pain Physician. 2020 Aug;23(4S):S469-S472. Pain Physician. 2020. PMID: 32942809 No abstract available.
Similar articles
-
COVID-19: The outbreak caused by a new coronavirus.Bol Med Hosp Infant Mex. 2020;77(2):47-53. doi: 10.24875/BMHIM.20000039. Bol Med Hosp Infant Mex. 2020. PMID: 32226003 Review. English.
-
2019 novel coronavirus (2019-nCoV) outbreak: A new challenge.J Glob Antimicrob Resist. 2020 Jun;21:22-27. doi: 10.1016/j.jgar.2020.02.021. Epub 2020 Mar 7. J Glob Antimicrob Resist. 2020. PMID: 32156648 Free PMC article. Review.
-
Novel coronavirus 2019-nCoV: prevalence, biological and clinical characteristics comparison with SARS-CoV and MERS-CoV.Eur Rev Med Pharmacol Sci. 2020 Feb;24(4):2012-2019. doi: 10.26355/eurrev_202002_20379. Eur Rev Med Pharmacol Sci. 2020. PMID: 32141570
-
The SARS, MERS and novel coronavirus (COVID-19) epidemics, the newest and biggest global health threats: what lessons have we learned?Int J Epidemiol. 2020 Jun 1;49(3):717-726. doi: 10.1093/ije/dyaa033. Int J Epidemiol. 2020. PMID: 32086938 Free PMC article.
-
Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding.Lancet. 2020 Feb 22;395(10224):565-574. doi: 10.1016/S0140-6736(20)30251-8. Epub 2020 Jan 30. Lancet. 2020. PMID: 32007145 Free PMC article.
Cited by
-
Proton pump inhibitors and gastrointestinal symptoms among patients with COVID-19 infection.Ann Med. 2024 Dec;56(1):2355581. doi: 10.1080/07853890.2024.2355581. Epub 2024 Jun 1. Ann Med. 2024. PMID: 38823421 Free PMC article.
-
Factors associated with cognitive impairment and the quality-of-life among COVID-19 survivors working as healthcare workers.Narra J. 2024 Apr;4(1):e658. doi: 10.52225/narra.v4i1.658. Epub 2024 Mar 20. Narra J. 2024. PMID: 38798859 Free PMC article.
-
Small Molecule Drugs Targeting Viral Polymerases.Pharmaceuticals (Basel). 2024 May 20;17(5):661. doi: 10.3390/ph17050661. Pharmaceuticals (Basel). 2024. PMID: 38794231 Free PMC article. Review.
-
SARS-CoV-2 Neutralization Assays Used in Clinical Trials: A Narrative Review.Vaccines (Basel). 2024 May 18;12(5):554. doi: 10.3390/vaccines12050554. Vaccines (Basel). 2024. PMID: 38793805 Free PMC article. Review.
-
Glycosylation Modulation Dictates Trafficking and Interaction of SARS-CoV-2 S1 Subunit and ACE2 in Intestinal Epithelial Caco-2 Cells.Biomolecules. 2024 Apr 30;14(5):537. doi: 10.3390/biom14050537. Biomolecules. 2024. PMID: 38785944 Free PMC article.
References
-
- Gorbalenya A.E., Baker S.C., Baric R.S., de Groot R.J., Drosten C., Gulyaeva A.A. Severe acute respiratory syndrome-related coronavirus: the species and its viruses—a statement of the Coronavirus Study Group. bioRxiv. 2020 Feb 11 doi: 10.1101/2020.02.07.937862. - DOI
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous